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Abstract: Respiratory tract infections (RTIs) represent a serious problem because they are 
one of the most common cause of human death by infection. The search for the treatment 
of those diseases has therefore a great importance. In this study we provide an overview of 
the currently available treatments for RTIs with particular attention to chronic obstructive 
pulmonary diseases exacerbations and recurrent respiratory infections therapy and a description 
of bacterial lysate action, in particular making reference to the medical literature dealing with 
its clinical efﬁ  cacy. Those studies are based on a very large number of clinical trials aimed to 
evaluate the effects of this drug in maintaining the immune system in a state of alert, and in 
increasing the defences against microbial infections. From this analysis it comes out that bacterial 
lysates have a protective effect, which induce a signiﬁ  cant reduction of the symptoms related 
to respiratory infections. Those results could be very interesting also from an economic point 
of view, because they envisage a reduction in the number of acute exacerbations and a shorter 
duration of hospitalization. The use of bacterial lysate could therefore represent an important 
means to achieve an extension of life duration in patients affected by respiratory diseases. 
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Background and introduction
Respiratory tract infections (RTIs) represent one of the most common and important 
causes of human disease in terms of morbidity, mortality, and economic cost to society. 
RTIs are the most common, and potentially the most severe, infections treated by 
health care practitioners. Lower RTIs, along with inﬂ  uenza, are the most common 
cause of death by infection in the United States. Risk factors for pneumonia and other 
respiratory tract infections include: extremes of age (very young and elderly), smok-
ing, alcoholism, immunosuppression, and comorbid conditions (File 2000). We can 
distinguish two main clinical manifestations of relevant impact: acute exacerbations 
of chronic bronchitis (AECB), and recurrent respiratory infections (RRI).
Recurrent respiratory infections (RRI) are characterized by at least three episodes 
of fever, locoregional inﬂ  ammation, cough, asthma, wheezing without severe impair-
ment of respiratory functions. This syndrome is frequent both in pediatric and in adult 
patients accounting for the principal cause of absence from school and work during 
winter time. RRI involve both upper and lower respiratory tract and are caused by 
a wide panel of microorganisms. In particular, viral infections, caused by inﬂ  uenza 
viruses, parainﬂ  uenza viruses, respiratory syncitial virus, adenovirus, rhinoviruses, are 
the original cause of the disease but recurrences are also caused by bacteria, including 
Acinetobacter spp., Chlamydia pneumoniae, Enterobatteriacee, Hemophilous inﬂ  u-
enzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, 
Nocardia asteroids, Pasturella multocida, Pseudomonas aeruginosa, Staphylococcus International Journal of COPD 2007:2(3) 336
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aureus, Stenotrophomonas maltophilia, Streptococcus pneu-
moniae and Streptococcus pyogenes (group A).
Chronic obstructive pulmonary disease (COPD) is a state 
characterized by airﬂ  ow limitation that is not fully reversible. 
The airﬂ  ow limitation is usually both progressive and associ-
ated with an abnormal inﬂ  ammatory response of the lungs 
to noxious particles or gases. A diagnosis of COPD should 
be considered in any patient who presents with symptoms of 
cough, sputum production, or dyspnoea, and/or has a history 
of exposure to the risk factors for the disease. Clinical symp-
toms and signs, such as an abnormal shortness of breath and 
increased forced expiratory time, can be used to help with 
the diagnosis. Chronic cough and sputum production often 
precede the development of airﬂ  ow limitation by many years, 
although not all individuals with cough and sputum produc-
tion go on to develop COPD. The classiﬁ  cation of Severity 
is shown in Table 2. The pathogenesis of COPD is charac-
terized by chronic inﬂ  ammation throughout the airways, 
parenchyma, and pulmonary vasculature. Macrophages, 
T lymphocytes (predominately CD8), and neutrophils are 
increased in various parts of the lung. Inﬂ  ammation of the 
lungs is caused by exposure to inhaled noxious particles 
and gases. Cigarette smoke can induce inﬂ  ammation and 
directly damage the lungs. Pathologic changes in the lungs 
lead to corresponding physiologic changes characteristic of 
the disease, including mucus hypersecretion, ciliary dys-
function, airﬂ  ow limitation, pulmonary hyperinﬂ  ation, gas 
exchange abnormalities, pulmonary hypertension, and cor 
pulmonale. The destruction of alveolar attachments, which 
inhibits the ability of the small airways to maintain patency, 
plays a smaller role. In advanced COPD, peripheral airways 
obstruction, parenchymal destruction, and pulmonary vascu-
lar abnormalities reduce the lung’s capacity for gas exchange, 
producing hypoxemia and, later on, hypercapnia. Pulmonary 
hypertension, which develops late in the course of COPD 
(Stage III: Severe COPD), is the major cardiovascular com-
plication of COPD and is associated with the development 
of cor pulmonale and a poor prognosis.
Patients with chronic obstructive pulmonary disease 
(COPD) are prone to exacerbations, which account for sig-
niﬁ  cant morbidity and mortality and are a key determinant 
of health-related quality of life. (Seemungal et al 1998) 
COPD exacerbations are deﬁ  ned as a change in the patient’s 
chronic respiratory symptoms sufﬁ  cient to warrant a change 
in management (Celli et al 2004; Global Initiative for Chronic 
Obstructive Lung Disease 2005)
The cardinal symptoms of COPD exacerbations 
are increase in dyspnoea, sputum volume and sputum 
purulence development (named the “Anthonisen’s 
criteria”) (Anthonisen NR 1987). There is considerable 
heterogeneity in the character, frequency, and time course 
of COPD exacerbations, which cannot be accounted for 
solely on the basis of degrees of airway obstruction or 
disease severity.
The lower airways of 25% to 50% of COPD patients are 
colonized by bacteria, especially noncapsulated Haemophi-
lus inﬂ  uenzae, Streptococcus pneumoniae, and Moraxella 
catarrhalis (Anthonisen et al 1987; Cabello 1997).
The predominant bacteria recovered in the lower air-
ways of patients with mild exacerbations are H. inﬂ  uenzae, 
S. pneumoniae and M. catarrhalis, whereas in severe COPD 
requiring mechanical ventilation gram negative bacilli, and 
P. aeruginosa are more frequent (Papi et al 2006). Lower 
airway bacterial colonization is increasingly recognized as 
an independent stimulus to airway inﬂ  ammation (Sethi et al 
2001) It can modulate the character and frequency of COPD 
exacerbations (Patel et al 2002).
A signiﬁ  cant role in the aetiology of acute exacerbations 
of chronic bronchitis seems to be played also by viruses, 
responsible of almost 40% of the exacerbations. (Seemungal 
et al 2001).
Pharmacological treatments: 
systemic overview
The currently available treatments for COPD therapy 
include:
Bronchodilators (Evidence A)
Bronchodilator medications are central to the symptom-
atic management of COPD (Vathenen et al 1998; Gross 
et al 1989; Chrystyn et al 1988; Higgins et al 1991) 
(Evidence A). They are given either on an as-needed basis 
for relief of persistent or worsening symptoms, or on a regu-
lar basis to prevent or reduce symptoms. The side effects 
of bronchodilator therapy are pharmacologically predict-
able and dose dependent. Adverse effects are less likely, 
and resolve more rapidly after treatment withdrawal. All 
categories of bronchodilators have been shown to increase 
exercise capacity in COPD, without necessarily producing 
signiﬁ  cant changes in FEV1 (Ikeda et al 1995; Guyatt et al 
1987a; Man et al 2004; O’Donnell et al 2004) (Evidence A). 
Regular treatment with long-acting bronchodilators is more 
effective and convenient than treatment with short-acting 
bronchodilators, but also more expensive (Mahler et al 
1999; Dahl et al 2001; Oostenbrink et al 2002; Vincken 
et al 2002) (Evidence A).International Journal of COPD 2007:2(3) 337
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Inhaled glucocorticosteroids 
Regular treatment with inhaled glucocorticosteroids does 
not modify the longterm decline of FEV1 in patients with 
COPD (Pauwels et al 1999; Vestbo et al 1999; Burge et 
al 2000; The Lung Health Study Research Group 2000). 
However, regular treatment with inhaled glucocorticoste-
roids is appropriate for symptomatic COPD patients with 
an FEV1 <50% predicted (Stage III: Severe COPD and 
Stage IV: Very Severe COPD) and repeated exacerbations 
(for example, 3 in the last three years) (Mahler et al 2002; 
Szafranski et al 2002; Calverley et al 2003a; Jones et al 
2003) (Evidence A). This treatment has been shown to 
reduce the frequency of exacerbations and thus to improve 
health status (Spencer et al 2004) (Evidence A). Withdrawal 
from treatment with inhaled glucocorticosteroids can lead to 
exacerbations in some patients. Inhaled glucocorticosteroid 
combined with a long-acting β2-agonist is more effective 
than the individual components (Mahler et al 2002; Calver-
ley et al 2003; Szafranski et al 2002; Hanania et al 2003; 
Calverley et al 2003b) (Evidence A).
Mucolytic (mucokinetic, mucoregulator) 
agents (ambroxol, erdosteine, 
carbocysteine, iodinated glycerol)
The regular use of mucolytics in COPD has been evaluated 
in a number of long-term studies with controversial results 
(Allegra et al 1996; Guyatt et al 1987b; Petty 1990). The 
majority of the studies showed no effect of mucolytics on 
lung function or symptoms, although some of them reported 
a reduction in the frequency of exacerbations. A Cochrane 
collaborative review performed a meta-analysis of all the 
available data, including those from a number of abstracts 
(Poole and Black 2003). A statistically signiﬁ  cant reduction 
in the number of episodes of chronic bronchitis was found in 
patients treated with mucolytics compared to those receiving 
placebo. However, those data are not easy to interpret, as 
the follow-up ranged from 2 to 6 months and all the patients 
had an FEV1 > 50% predicted. Although a few patients with 
viscous sputum may beneﬁ  t from mucolytics (Siafakas et al 
1995; American Thoracic Society 1986), the overall beneﬁ  ts 
seem to be very small. Therefore, the widespread use of these 
agents cannot be recommended on the basis of the present 
evidence (Evidence D).
Antioxidant agents
Antioxidants, in particular N-acetylcysteine, have been shown 
to reduce the frequency of exacerbations and could have a 
role in the treatment of patients with recurrent exacerbations 
(Boman et al 1983;  British Thoracic Society Research Com-
mittee 1985;  Rasmussen and Glennow 1988; Hansen et al 
1994) (Evidence B). However, before their routine use can 
be recommended, the results of ongoing trials have to be 
carefully evaluated.
Antitussives
Cough, although it is sometimes a troublesome symptom in 
COPD, has a signiﬁ  cant protective role (Irwin et al 1998). Thus 
the regular use of antitussives is contraindicated in stable COPD 
(Evidence D). For classiﬁ  cation of evidences, see Table 1.
Table 1 Classiﬁ  cation of evidence
Evidence  Category  Sources of evidence deﬁ  nition
A   Randomized control trial  Rich body of data. Evidence is from endpoints of well designed RCTs that provide a 
    consistent pattern of ﬁ  ndings in the population for which the recommendation is 
    made. Category A requires substantial numbers of studies involving substantial 
    numbers of participants.
B   Randomized control trial  Limited body of data. Evidence is from endpoints of intervention studies that 
    include only a limited number of patients, post hoc or subgroup analysis of RCTs, 
    or meta-analysis of RCTs. In general, Category B pertains when few randomized 
    trials exist, they are small in size, or they were undertaken in a population that 
    differs from the target population of the recommendation, or the results are 
   somewhat  inconsistent.
C  Nonrandomized trials  Observational studies. Evidence is from outcomes of uncontrolled or non 
    randomized trials or from observational studies.
D   Panel   Consensus Judgment. This category is used only in cases where the provision of 
    some guidance was deemed valuable but the clinical literature addressing the 
    subject was deemed insufﬁ  cient to justify placement in one of the other categories. 
    The Panel Consensus is based on clinical experience or knowledge that does not 
    meet the above listed criteria.International Journal of COPD 2007:2(3) 338
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Antibiotics
In several large-scale controlled studies (Francis and Spicer 
1960; Francis et al 1961; Fletcher et al 1966), the prophy-
lactic, continuous use of antibiotics was shown to have no 
effect on the frequency of exacerbations in COPD. Another 
study examined the efﬁ  cacy of winter chemoprophylaxis over 
a period of 5 years and concluded that there was no beneﬁ  t 
(Johnston et al 1969). Thus, on the present evidence, the use 
of antibiotics, other than for treating infectious exacerbations 
of COPD and other bacterial infections, is not recommended 
(Isada and Stoller 1994; Siafakas Bouros 1998) (Evidence A). 
In the case of an acute exacerbation, antibiotic therapy 
signiﬁ  cantly shortens the duration of symptoms and can be 
cost-effective. Over the past 50 years, virtually all classes of 
antimicrobial agents have been studied in AECB. Important 
considerations include penetration into respiratory secre-
tions, spectrum of activity and antimicrobial resistance. 
Those factors limit the usefulness of drugs such as amoxi-
cillin, erythromycin and trimethoprim-sulfamethoxazole. 
Extended-spectrum oral cephalosporins, newer macrolides 
and doxycycline have demonstrated efﬁ  cacy in clinical tri-
als. Amoxicillin-clavulanate and ﬂ  ouoroquinolones should 
generally be reserved for patients with more severe disease. 
A number of investigational agents; including ketolides and 
newer quinolones; hold promise for treatment of AECB. 
(Dever et al 2002).
Innate and adaptive immunity 
modulation in preventing and 
treating respiratory infection
The potentiation of both speciﬁ  c and non speciﬁ  c immunere-
sponse has been considered a central point in the treatment of 
recurrences in respiratory tract infections. Speciﬁ  c immunity 
against viruses (such as inﬂ  uenza virus) and bacteria (Strep-
tococcus pneumoniae) can be raised using speciﬁ  c treatment 
with vaccines. This is the case of inﬂ  uenza vaccines and 
pneumococcal vaccine.
Inﬂ  uenza vaccines
Inﬂ  uenza vaccines can reduce serious illness (Wongsura-
kiat et al 2004) and death in COPD patients by about 50% 
(Nichol et al 1994; Wongsurakiat et al 2003) (Evidence A). 
Vaccines containing killed or live, inactivated viruses are 
recommended (Edwards et al 1994) as they are more effec-
tive in elderly patients with COPD (Hak et al 1998). The 
strains are adjusted each year for appropriate effectiveness 
and should be given once (in autumn) or twice (in autumn 
and winter) each year.
Pneumococcal vaccine
A pneumococcal vaccine containing 23 virulent serotypes 
has been used (Williams and Moser 1986; Davis 1987; Sim-
berkoff et al 1996) (Evidence B). 
The potentiation of nonspeciﬁ  c and speciﬁ  c immunere-
sponse against other bacteria (such as the bacteria shown as 
the cause of recurrent infection of the respiratory tract), can 
be obtained using polyvalent bacterial lysate. This category 
of drugs includes different kinds of bacterial extracts, and 
a different number of bacterial species (polyvalent extracts) 
obtained through different ways of lysis, both chemical or 
mechanical (PMBL, PCBL). We will further on discuss the 
effects of this kind of drugs, through an analysis of Random-
ized Controlled Trials published to date. 
Characteristics of bacterial lysate
Bacterial lysate are constituted by a mixture of bacterial an-
tigens derived from different bacterial species, according to 
the considered extract. The more often included species are: 
Staphylococcus aureus, Streptococcus viridans, Streptococcus 
pneumoniae (6 strains), Streptococcus pyogenes, Klebsiella 
pneumoniae, Klebsiella ozenae, Moraxella catarrhalis, He-
mophylous inﬂ  uenzae. Each extract is prepared with billions of 
these bacteria. Antigens are obtained following a mass culture 
of reference bacterial strains, using a chemical or mechanical 
Table 2 Classiﬁ  cation of severity according to GOLD guide-
lines. (http://goldcopd.com/ GOLD Global Iniative for Cronich 
Obstructive Lung Disease)
Stage Characteristics
0: at risk  • Normal spirometry.
 •  Chronic symptoms (cough, sputum 
     production).
I: Mild COPD  • FEV1/FVC < 70%.
 •  FEV1 > or = 80% predicted.
 •  With or without chronic symptoms
     (cough, sputum production),
II: Moderate COPD  • FEV1/FVC < 70%,
 •  50% < or = FEV1 < 80% predicted.
 •  With or without chronic symptoms 
     (cough, sputum production).
III: Severe COPD  • FEV1/FVC < 70%.
 •  30% < or = FEV1 < 50% predicted.
 •  With or without chronic symptoms 
     (cough, sputum production).
IV: Very Severe COPD  • FEV1/FVC < 70%.
 •  FEV1 < 30% predicted or FEV1 
     < 50% predicted plus chronich 
     respiratory failure.
Based on postbronchodilator FEV1International Journal of COPD 2007:2(3) 339
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lysis of cells and lyophilization. Different antigens are mixed 
and excipients are added in order to prepare the tablets.
Bacterial lysate is both a specific and non specific 
immunostimulating agent, indicated for the prevention and 
treatment of respiratory infections, including sequelae to 
common cold and inﬂ  uenza. In particular it is useful for the 
treatment of acute and chronic bronchitis, anginas, tonsillitis, 
pharyngitis, laryngitis, rhinitis, sinusitis, and otitis. It can also 
be used for infections resistant to common antibiotics and 
for the sequelae to bacterial and viral infections. 
The more usual treatment schedule for PMBL is the 
following:
–acute events: one tablet per day to dissolve under the 
tongue, (for a minimum of ten days) until the symptoms 
disappear.
–long term treatment: one tablet per day to dissolve under 
the tongue for 10 consecutive days, followed by 20 days’ rest. 
The cycle is repeated for three consecutive months.
Mode of action of bacterial lysate
The capacity of a virtually intact microbe to activate 
resting monocytic-macrophage cells is strictly linked to 
the presence of structures belonging to the bacterial cell 
wall (for example, protido-glycane or lipopolysaccharide) 
against which some receptor structures (such as the so 
called toll like receptors -TLR) are specific directed. TLR 
are expressed on the surface of monocyte membrane. 
The interaction between bacterial structures and TLR 
results in the activation of monocytes, their differentiation 
to immature dendritic cells and the following maturation 
to mature dendritic cells, able to be considered a suitable 
professional antigen presenting cell. The use of bacterial 
antigens obtained by mechanical or chemical lysis is thus 
able to activate monocytic-macrophagic cells of the sub-
mucosa, inducing the differentiation through immature 
dendritic cells and their maturation in mature dendritic 
cells. The activation of such a mechanism results in a 
suitable stimulation of the immune-response.
The presentation of bacterial antigens on mature dendritic 
cells results in the stimulation of the T cell compartment 
(with a consequent induction of a powerful helper function) 
and of the B cell compartment of the immune-response, 
with a following maturation to plasmacells and secretion 
of antibodies speciﬁ  cally directed to the administered. The 
administration of bacterial lysate is thus able to induce a T 
helper function and a maturation of B speciﬁ  c lymphocytes 
resulting in the production of IgA salivary antibodies directed 
to the administered mixture of antigens.
The secretion of antibodies directed to bacterial antigens 
has a positive function only in the case of these antibodies 
having the capability to opsonize living bacterial cells, thus 
favouring the phagocytosis and the killing mediated by pro-
fessional phagocytes, such as granulocytes. 
All these ﬁ  ndings indicate that the maturation of dendritic 
cells, the speciﬁ  c activation of the T and B cell population 
of lymphocytes, and the resulting production of IgA in the 
respiratory mucosa speciﬁ  cally directed to the antigens 
administered, characterized by the capacity of opsonizing 
living bacteria thus allowing their engulfment and killing in 
phagocytes, represent the actual pathway for the potentia-
tion of a both nonspeciﬁ  c (dendritic cells and phagocytes) 
and speciﬁ  c (T and B cells) immune-response, resulting in 
a prophylactic effect on recurrent infections of the respira-
tory tract.
Bacterial lysate clinical efﬁ  cacy: 
literature review
The effects of bacterial lysate as an immunostimulatory agent 
has been debated in many clinical trials.
By performing a simple research on PubMed directory 
of the terms “bacterial lysate”, and limiting the search only 
to randomized clinical trials, it is possible to ﬁ  nd more than 
thirty papers. The aim of those studies, all published during 
the last twenty years, is to evaluate the effects of this class 
of drugs in maintaining the immune system in a state of 
alert, and in raising a defence against microbial infections, 
eventually leading to a reduction in their number.
Those studies are very different and heterogeneous. In 
fact the populations and samples of those trials are various, 
being representative of diverse diseases, such as: recurrent 
respiratory infections of upper and/or lower airways; chronic 
bronchitis; rhino-sinusitis and other ENT infections; chronic 
obstructive pulmonary disease. Even the age of patients 
included is different: many trials are conducted on pediatric 
patients (Braido et al). 
We will brieﬂ  y discuss the ﬁ  ndings of these RCTs, ana-
lysing them separately, according to the characteristic of the 
patients included.
Pediatric trials
A pilot study involving 89 children pointed out that the 
administration of polivalent mechanical bacterial lysate 
could lead to a signiﬁ  cant decrease in recurrent respiratory 
infections in patients treated with this drug, compared to the 
controls on the same children during the previous year; also 
information indexes were signiﬁ  cantly lower in the treated International Journal of COPD 2007:2(3) 340
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information group, and the values of B-lymphocytes were 
found to be increased (Rosaschino and Cattaneo 2004). 
Even in patients from 3 to 6 years of age, affected by 
recurrent respiratory infections and IgG deﬁ  ciency, a RCT 
proved the beneﬁ  cial effect of bacterial lysate (Del-Rio-
Navarro et al 2003). 
Another RCT that included 232 children aged 3–5 years, 
showed that the treatment with PMBL signiﬁ  cantly reduced 
the rate of upper respiratory tract infections, being this 
reduction higher in children affected more frequently by this 
kind of infections; the drug was also safe and well tolerated 
compared to placebo (Schaad et al 2002).
Another RCT involving 188 pediatric patients and lasting 
more than one year, put in evidence that the rate of infec-
tion was reduced of 50% in treated patients, and this was 
sustained for half a year after the end of drug administration; 
drug reactions were few, transient, expected and non serious 
(Ruah et al 2001).
A RCT lasting one year, including 54 children aged 1–12 
years, evaluated for the two groups of patients (active/pla-
cebo) the number of acute respiratory tract infections and 
their duration, and also the number of antibiotic courses 
needed. The results showed a reduction in the number of 
infections, and a more signiﬁ  cant reduction in antibiotic 
requirements and in the duration of the infection episodes in 
the treated group compared to placebo (Gutierrez-Tarango 
and Berber 2001).
56 young patients affected by subacute sinusitis were 
involved in a RCT lasting 6 months, evaluating the effects of 
bacterial lysate added to amoxicillin/clavulanate. The results 
pointed out that the cure and improvement of the patients in 
the active group were faster, and that these patients expe-
rienced a lower incidence of respiratory infections (Gomez 
Barreto et al 1998).
A bigger trial involving 423 children attending day-care 
centers (subjects with a higher risk of infection) showed that, 
during the period of treatment with bacterial lysate, treated 
children had a relative risk of 0.52 to present three or more 
episodes of upper respiratory infections (Collet et al 1993).
A much older study also revealed that, in children with 
rhinosinusitis, the treatment with bacterial lysate decreases 
the incidence and duration of infectious episodes and the 
number and duration of concomitant treatments; moreover, 
the clinical response showed a correlation with an increase 
in serum levels of IgA (Zagar and Loﬂ  er-Badzek 1989). 
Quite a big trial involving 825 children in the treatment 
group and 327 in the placebo one, pointed out that the ad-
ministration of a bacterial lysate applied intranasally for 
6 months does not reduce the number of acute respiratory 
diseases compared to placebo (Sramek et al 1986).
Adult patient trials
Concerning the studies focused on samples of adult patients 
(Ahrens and Wiedenbach 1984; Keller 1984; Heintz et al 
1989; Cvoriscec et al 1989; Debbas and Derenne 1990; De-
belic and Eckenberger 1992; Orcel et al 1994; Collet et al 
1997; Rutishauser et al 1998; Tielemans et al 1999; Li et al 
2004; Steurer-Stey et al 2004; Tricarico et al 2004; Macchi 
and Vecchia 2005), we will discuss them separately, accord-
ing to the disease considered (recurrent respiratory infections, 
chronic bronchitis, and COPD). 
Recurrent respiratory infections
A recent study, a RCT involving 140 patients with a history 
of recurrent respiratory infections, compared the effects of 
bacterial lysate obtained through mechanical lysis (pts in the 
ﬁ  rst group) to the effects of bacterial lysate obtained through 
chemical lysis (pts in the second group) and to the effects of 
no treatment at all (pts in the third group, control); the end 
points were: the number of upper respiratory tract infections, 
the number of patients free from disease, the duration of 
infectious episodes, the number of working days lost because 
of the disease, the need for antibiotic treatment. The results 
for each one of the end points showed the efﬁ  cacy of the two 
treatments, but the best results were achieved with the treat-
ment with the bacterial lysate obtained through mechanical 
lysis, and were signiﬁ  cantly superior to those achieved with 
placebo and also with the bacterial lysate obtained through 
chemical lysis (Macchi and Vecchia 2005).
A particular study evaluated the efﬁ  cacy of bacterial 
lysate in preventing upper respiratory tract infections in 
subjects belonging to a speciﬁ  c setting, that is a commu-
nity of cloistered nuns. 47 nuns were allocated into two 
different groups, active treatment and placebo. The results 
showed a signiﬁ  cant lower number in respiratory infec-
tions, and a shorter duration, in the active treatment group; 
moreover, a signiﬁ  cant increase in serum Ig and salivary 
IgA was recorded in the active treatment group (Tricarico 
et al 2004).
Other trials have shown the efﬁ  cacy of bacterial lysate 
in treating patients with recurrent respiratory infections 
(Ahrens and Wiedenbach 1984; Debelic and Eckenberger 
1992; Rutishauser et al 1998 ), even in group of patients with 
an increased risk, such as patients in hemodialysis treatment 
(Tielemans 1999). A particular attention was also given to the 
investigation of the tolerability of such kind of treatments, International Journal of COPD 2007:2(3) 341
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and the results were excellent (Ahrens and Wiedenbach 1984; 
Debelic and Eckenberger 1992).
One trial (Heintz et al 1989) was designed to test the 
efﬁ  cacy of bacterial lysate in treating patients suffering from 
chronic purulent sinusitis. This study, carried over on 284 
patients for a duration of six months, showed the efﬁ  cacy of 
treatment in reducing cough, purulent nasal discharge and 
headache, on the basis of the score of symptoms.
Chronic bronchitis
Since acute bronchitis is a major source of morbidity in 
elderly patients, a RCT involving 354 patients living in 
institutions for elderly was designed, in order to assess the 
effects of treatment with bacterial lysate on the incidence of 
lower respiratory tract infections. A reduction of 28% was 
observed, and this was due to a 40% reduction in episodes of 
acute bronchitis, with no differences in the incidence of pneu-
monia in the two groups. During the 6 months of duration of 
the trial, a larger number of patients in the active treatment 
group didn’t experience any episode of acute bronchitis, and 
a reduction in antibiotic prescription in the same group was 
recorded (Orcel et al 1994).
Another 104 patients affected by chronic bronchitis were 
involved in a RCT comparing bacterial lysate to placebo 
over a period of 6 months. The results showed a signiﬁ  cant 
reduction of the duration of acute episodes and fever in the 
treatment group, with a concomitant sparing-effect on the 
use of antibiotics, an increase in serum IgA levels and in 
T-lymphocyte counts (Cvoriscec et al 1989).
A previous, much older study (Keller 1984), evalu-
ated the effect of bacterial lysate in patients with chronic 
bronchitis. The conclusions on the effects of this treatment 
on clinical symptoms didn’t reach a statistically signiﬁ  cant 
beneﬁ  t compared to placebo, and the authors advocated for 
further studies, with more patients, and with a longer period 
of observation.
COPD
One of the ﬁ  rst RCT on the use of bacterial lysate in COPD 
patients (Debbas and Derenne 1990), lasting 6 months and 
involving 265 patients, demonstrated a statistically signiﬁ  cant 
reduction of infectious events, and a concomitant reduction 
in the use of antibiotics. 
A well-built RCT (Collet et al 1997) recruited 381 patients 
with COPD and followed them for 6 months. This trial pointed 
out that the risk of having at least one exacerbation during the 6 
months was similar in both groups. The most signiﬁ  cant result 
showed a clear reduction in the total number of days of hos-
pitalization for respiratory problems in the group treated with 
bacterial lysate (287) compared to the placebo group (642). 
Also the risk of being hospitalized was reduced for the same 
patients group (16.2% vs 23.2%). Moreover, the number of 
deaths observed was reduced in the treatment group (2 vs 6), 
but without statistical signiﬁ  cance. These results showed that 
immunostimulating agents could be useful for treating patients 
with COPD, being able to reduce the likelihood of severe 
respiratory events possibly responsible for hospitalization. 
Another, more recent, RCT (Li et al 2004) included 90 
patients. The considered endpoints were: the frequency of 
acute exacerbations, symptom scores, lung function, all 
recorded for one year after the end of the treatment. The 
results showed, in the group treated with bacterial lysate 
compared to the placebo group: a decrease in incidence, 
duration, and severity of acute exacerbation; a reduction in 
the course of antibiotics; an improvement in symptom scored 
and a higher bacterial clearance rate in sputum cultures. 
Recently, a systematic review and metanalysis was pub-
lished (Steurer-Stey et al 2004), investigating the use of oral 
puriﬁ  ed bacterial extracts in the treatment of patients affected 
by COPD. An extensive and systematic search for random-
ized clinical trials in all the electronic databases, biographies, 
and data from manufacturers was performed. Eventually, a 
total of 13 studies, corresponding to almost two thousands 
patients, were included in the analysis. Concerning the pre-
vention of exacerbations, the results showed that the main 
treatment effect was found in the smaller studies, the ones 
with lower quality score. As a consequence, the combination 
of all the data results in high heterogeneity, and the difference 
between active extracts and placebo does not reach statistical 
signiﬁ  cance. The metanalysis also showed a shorter duration 
of exacerbations in the active treatment groups. The improve-
ment of symptoms, as assessed both by the patients and the 
observers; was in favour of bacterial extracts. Hospitalization 
admission resulted lower in the bacterial extracts group (but 
data were drawn only from one study) (Collet et al 1997). This 
systematic review clearly points out that a strong evidence 
for the prevention of exacerbation in COPD patients through 
the use of bacterial extracts is still missing; nonetheless, an 
improvement in symptoms has been underlined, as well as 
a shorter duration of exacerbation, and a reduction of hospi-
talization. Anyway, those conclusions are relevant as there 
could be some important economic consequences if a reduc-
tion of hospitalization can be prospected by the use of those 
relatively cheap drugs, which can be applied intermittently. 
Also a beneﬁ  t on symptoms, as perceived by the patients, is 
important, as a reﬂ  ection of a better quality of life.International Journal of COPD 2007:2(3) 342
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Table 3 Pediatric trials
Pediatric trials
Author Year  Disease  Patients  Preparation  Results
Rosaschino  2004 Recurrent  respiratory  89  PMBL  Infections,
    infections      markers of inﬂ  ammation,
         Lymph  B
Del Rio Navarro  2003  Recurrent respiratory  40  OM85-BV  Clinical beneﬁ  t
   infections
Schaad  2002  Upper respiratory tract  232  OM85  URTI rate,
    infections      good safety and tolerance
Ruha  2001  Respiratory tract infections  188  LW50020  Infection rate,
         safety  assessment
Gutierrez-Tarango 2001  Acute  respiratory  tract  54  OM85-BV  infections,
   infections      antibiotics  requirements,
          duration of infections
Gomez-Barreto 1998 Sub-acute  sinusitis  56  OM85-BV  Effective,
          incidence of respiratory 
         infections
Collet  1993  Upper respiratory  423  OM85-BV  Risk of presenting > or = 3 
    infections      episodes of URI
Zagar  1998  Rhinosinusitis  51  BV  Infection number and duration,
         IgA  levels
Sranek  1986  Acute respiratory diseases  1252  IRS19 (intranasal)  Not effective in  ARD
Table 4  Adult trials
Adult trials
Author Year  Disease  Patients  Preparation  Results
Macchi  2005  Recurrent respiratory  140  PMBL/CLBL  Effectiveness of both treatments
   infections
Tricarico  2004  Recurrent respiratory  47 (closed  MLBL  Infections, 
    infections  community)    duration of infections,
          Ig and  salivary IgA
Rutischauser  1998 Recurrent  respiratory    LW50020    Effective, 
   infections      treatment  beneﬁ  t
Debelic  1992  Recurrent respiratory  620    excellent tolerability,
    infections      frequency and severity of infections
Ahrens  1984 Recurrent  respiratory  230  BV  Signiﬁ  cant protective effect
   infections
Tielemans  1999  Recurrent respiratory  40  IBE  Effectivness in pts in hemodialisys
   infections
Heintz  1989  Chronic purulent sinusitis  284  BV  Effectiveness of treatment  
Orcel  1994  Chronic bronchitis  354 (living in  OM85-BV  Lower respiratory tract infections
       institutions)
Cvoriscec  1989  Chronic bronchitis  104  BV  Acute episodes,
         antibiotics  utilization, 
         IgA  and  T-Lymph
Keller  1984  Chronic bronchitis  75  BV  No signiﬁ  cant differences
Debbas  1990 Chronic  obstructive  265  OM85-BV  Infections, 
    Pulmonary disease      antibiotics intake,
Collet  1997  Chronic obstructive  381  OM85-BV  = risk of  at least one acute 
   Pulmonary  disease      exacerbation,
          days of hospitalization
Li  2004  Chronic obstructive  90  BV   Frequency of acute exacerbations,
    Pulmonary disease       antibiotics need,
             symptom  scoreInternational Journal of COPD 2007:2(3) 343
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Discussion and conclusions
As we have previously reported, bacterial lysates are pow-
erful inducers of a speciﬁ  c locoregional immune response 
that signiﬁ  cantly enhance the concentration of antibodies 
directed to antigenic structures of bacteria most commonly 
observed during infections of the upper respiratory tract. 
Those antibodies have the capability of opsonizing living 
bacteria, thus allowing the engulfment and killing mediated 
by human phagocytes, such as granulocytes. This activity is 
linked to the capacity of inducing a signiﬁ  cant reduction (or 
a complete disappearance) of signs and symptoms related to 
respiratory infections. 
This effect comes out also from the systematic analysis 
of medical literature, and is reﬂ  ected in the results of the 
randomized clinical trials. Those results underline an over-
all protective effect, with a different level of signiﬁ  cance, 
depending on the study design, the disease considered, and 
the type of patients involved. Both in pediatric and adult tri-
als, as reported in the Tables 3 and 4, we can ﬁ  nd a positive 
trend in the results: a general reduction of infection rates, a 
reduction of their duration, a beneﬁ  cial effect on symptoms, 
a reduction in the use of antibiotics. 
Those effects also have, as a direct consequence, impor-
tant economic implications. In the case of COPD, a reduction 
in the number of acute exacerbations, or a shorter duration of 
hospitalization, could represent an actual opportunity for cur-
tailing costs of management of such patients. In fact, patients 
with a moderate-severe COPD can experience a mean of at 
least 2 AECB/year (Miravitlles et al 1999). The most serious 
patients, besides experiencing more frequent exacerbations, 
are more frequently hospitalized, and for longer periods 
(Donaldson et al 2002). We also have to consider that AECB 
represent an important cause of death. A trial reported that, 
in a sample of 1000 hospitalized patients affected by severe 
COPD, when dismissed, 20% of them die within two months, 
33% within six years, and 43% within one year. (Hilleman 
et al 2000) The risk of death in COPD patients is strictly 
correlated with the frequency and gravity of exacerbations. 
As a consequence, it would be extremely useful to obtain a 
reduction of exacerbations, in order to extend the life dura-
tion of this kind of patients. Therefore, the use of bacterial 
lysate could represent an important means to achieve this 
prominent result. 
In conclusion, even though the results of the analyzed 
studies are encouraging, it would be worthwhile to build up 
new trials. Those new trials should include a higher number 
of patients, selected according to the disease and its severity, 
and should be well-designed trials in term of blinding and 
randomization procedures. This could permit to get even 
stronger evidence of their beneﬁ  cial effect, both on symptoms 
and on prevention of infections.
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